SPOTLIGHT -
Emerging Therapies for HCC Management
Read More
Metastatic HCC Unmet Needs
I/O Second-Line Treatment
REACH and REACH2 Trial Overview
Second-Line Therapy: Monoclonal Antibody
Second-Line Sequencing After IMbrave150 Regimen
R/R HCC: Second-Line Options
Frontline I/O: Clinical Trial Overviews
Frontline Therapy: Promising I/O Combinations
Phase 3 IMbrave150 Trial
Frontline Decision Factors for Metastatic Disease
HCC Treatment Algorithm: Asia and Europe
Transitioning From Locoregional to Systemic Therapy
HCC Diagnosis and Prognosis
The Evolving Role of Medical Oncologists and Hepatologists
HCC Global Screening Programs for At-Risk Populations
HCC Etiologic Risk Factors and Global Prevalence
Dr Berkenstock on ADC-Related Ocular Toxicities in Cervical and Ovarian Cancers
Dr Matalonis on the Management of Mirvetuximab Soravtansine-Related Toxicities in FRα+ Ovarian Cancer
Updated EMPOWER-Lung 3 Data Support Frontline Cemiplimab Plus Chemo in Advanced NSCLC
Neoadjuvant Nivolumab Plus Chemotherapy Retains EFS Advantage in Resectable NSCLC
